Pune-based Serum Institute of India Ltd continues to lead the Indian Biopharmaceutical Industry with a revenue of Rs 7201 crore for the year 2020-21 followed by Bangalore-based Biocon Ltd with Rs 5136 crore and Hyderabad-based Sanofi Healthcare India Pvt Ltd with Rs 1739 crore respectively.

Pune-based vaccine manufacturer Serum Institute of India (SII) recorded a revenue of Rs 7201 crore during FY 20-21, exhibiting a growth of 44 per cent in comparison to the revenue generation of Rs 5014 crore in FY 19-20.

At the beginning of FY 20-21, SII announced its partnership with the University of Oxford in the UK for the trial of its COVID-19 vaccine candidate Covishield, in coordination with the Indian Council of Medical Research (ICMR) and AstraZeneca. In the later months, the company entered into a landmark partnership with Gavi, The Vaccine Alliance and the Bill & Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for India and lowand middle-income countries (LMICs).

According to the government’s vaccine administration data, more than 150 crore doses of Covishield have been administered in India so far. Very recently, a book has been launched in the market chronicling the journey of SII’s COVID-19 vaccine Covishield. The coffee table book ‘The Shield: Covishield’ has been penned by Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute. During 2020, SII also collaborated with US-based Novavax for manufacturing the antigen component of NVX CoV2373, Novavax’ COVID 19 vaccine candidate. ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing based in the US, supported SII by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine candidate, NVX CoV2373.

Click here to read more....